Sanofi

Sanofi-aventis

Cecile Pascal

Alain Jean Braun

Eric Nicolai

Olivier Crespin

Olivier Venier

Claudie Namane

Francois Pacquet

Christophe Philippo

Fabrice Viviani

Gilles Courtemanche

Gilbert Marciniak

Bertrand Vivet

Yann Foricher

Patrick Mougenot

Nicolas Muzet

Michel Aletru

Stefan Gussregen

Bruno Cornet

The invention relates to bicyclic heterocyclic derivatives of general formula (I) to a process for preparing them and to the therapeutic use thereof. 

Pyrimidooxazocine derivatives as mTOR-inhibitors

The present invention relates to tetrahydroquinoxaline urea derivatives of formula (I) as defined herein, and, to their preparation and to their therapeutic application.

Substituted adamantanes and their therapeutic application

The invention relates to a compound of the general formula (I), as defined herein which is useful in modulating the activity of 11&#x3b2;-hydroxysteroid dehydrogenase type 1 (11&#x3b2;HSD1) and are useful for treating pathologies in which such modulation is beneficial, as in the case of metabolic syndrome or of noninsulin-dependent type 2 diabetes. The invention also relates to pharmaceutical preparations containing such a compound, processes for preparing and intermediates useful in the preparation of a such a compound.

Tetrahydroquinoxaline urea derivatives as modulators of 11&#x3b2;-hydroxysteroid dehydrogenase type 1

The invention relates to tropane urea derivatives of general formula (I) and to the application thereof as modulators of the activity of 11&#x3b2;-hydroxysteroid dehydrogenose type 1 (11&#x3b2;HSD1).

Tropane urea derivatives, preparation thereof and therapeutic application thereof as modulators of the activity of 11betaHSD1

The present invention relates to tetrahydroquinoxaline urea derivatives of Formula (I): as disclosed herein, to their preparation and to their therapeutic application.

Tetrahydroquinoxaline urea derivatives

The present invention is related to a compound of formula (I): wherein i, j, n, o, p, q, r, R, R, R, R, R, R, R, R, R, Rand Rare as defined herein, or an addition salt with an acid thereof, or a hydrate or solvate thereof, its preparation, pharmaceutical composition, and uses for treating a disease in which the enzyme 11&#x3b2;-HSD1 is involved.

Substituted quinoxalines, their preparation and their therapeutical use as 11&#x3b2;HSD1 modulators

The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment and in the prevention of obesity, diabetes and sexual dysfunctions that can affect both sexes, in the treatment of cardiovascular diseases, and also in anti-inflammatory uses or in the treatment of alcohol dependency.

Growing community of inventors

Paris, France

Cecile Pascal